• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Achilles Therapeutics plc (Amendment)

    2/14/23 4:00:27 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACHL alert in real time by email
    SC 13G/A 1 pt7213ga.htm SCHEDULE 13G/A, AMENDMENT #1
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.

    Securities and Exchange Commission, Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

    (Name of Issuer)

    Achilles Therapeutics plc

    (Title of Class of Securities)

    Ordinary shares, nominal value £0.001 per share¹

    (CUSIP Number)

    00449L102²

    (Date of Event Which Requires Filing of this Statement)

    December 31, 2022

    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:

    [  ] Rule 13d-1(b)

    [ x ] Rule 13d-1(c)

    [  ] Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).

    1The holdings reported herein are held in the form of American Depositary Shares ("ADS"), which
    each represent one ordinary share, nominal value of £0.001 per share of the Issuer (“Ordinary Shares”).
    2The CUSIP Number listed throughout this filing is the CUSIP assigned to the ADS of the Issuer.


    CUSIP No. 00449L102
    (1) Names of reporting persons    Point72 Asset Management, L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              1,413,809**
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       1,413,809**
     
    (9) Aggregate amount beneficially owned by each reporting person
    1,413,809**
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 3.6%
     
    (12) Type of reporting person (see instructions) PN
     


    **Consists of 1,413,809 American Depositary Shares, representing 1,413,809 Ordinary Shares.


    CUSIP No. 00449L102
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              1,413,809**
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       1,413,809**
     
    (9) Aggregate amount beneficially owned by each reporting person
    1,413,809**
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 3.6%
     
    (12) Type of reporting person (see instructions) CO
     


    **Consists of 1,413,809 American Depositary Shares, representing 1,413,809 Ordinary Shares.


    CUSIP No. 00449L102
    (1) Names of reporting persons    Cubist Systematic Strategies, LLC
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              0
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       0
     
    (9) Aggregate amount beneficially owned by each reporting person
    0
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0%
     
    (12) Type of reporting person (see instructions) OO
     



    CUSIP No. 00449L102
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              1,413,809**
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       1,413,809**
     
    (9) Aggregate amount beneficially owned by each reporting person
    1,413,809**
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 3.6%
     
    (12) Type of reporting person (see instructions) IN
     

     **Consists of 1,413,809 American Depositary Shares, representing 1,413,809 Ordinary Shares.

    Item 1(a) Name of issuer:

    Achilles Therapeutics plc

    Item 1(b) Address of issuer's principal executive offices:

    245 Hammersmith Road, London W6 8PW, United Kingdom

    2(a) Name of person filing:

    The holdings of the Issuer’s ordinary shares, nominal value £0.001 per share (“Ordinary Shares”)
    reported herein are held in the form of American Depositary Shares (“ADS”), which each
    represent one Ordinary Share.  This statement is filed by: (i) Point72 Asset Management, L.P.
    (“Point72 Asset Management”) with respect to Ordinary Shares held, in the form of ADSs, by an
    investment fund it manages; (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”)
    with respect to Ordinary Shares held, in the form of ADSs, by an investment fund managed by
    Point72 Asset Management; (iii) Cubist Systematic Strategies, LLC (“Cubist Systematic
    Strategies”) with respect to Ordinary Shares held, in the form of ADSs, by an investment fund it
    manages; and (iv) Steven A. Cohen (“Mr. Cohen”) with respect to Ordinary Shares held, in the
    form of ADSs, beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc.,
    and Cubist Systematic Strategies.

    2(b) Address or principal business office or, if none, residence:

    The address of the principal business office of (i) Point72 Asset Management,
    Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902;
    and (ii) Cubist Systematic Strategies is 55 Hudson Yards, New York, NY 10001.

    2(c) Citizenship:

    Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a
    Delaware corporation. Cubist Systematic Strategies is a Delaware limited liability company.
    Mr. Cohen is a United States citizen.

    2(d) Title of class of securities:

    Ordinary Shares, nominal value £0.001 per share

    2(e) CUSIP Number:

    00449L102

    Item 3.

    Not applicable


    Item 4. Ownership

    The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for
    each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.
    Such information is as of the close of business on December 31, 2022.

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and
    Mr. Cohen own directly no ADSs or Ordinary Shares. Pursuant to an investment
    management agreement, Point72 Asset Management maintains investment and voting
    power with respect to the securities held by an investment fund it manages. Point72 Capital
    Advisors Inc. is the general partner of Point72 Asset Management. Pursuant to an investment
    management agreement, Cubist Systematic Strategies maintains investment and voting power
    with respect to the securities held by an investment fund it manages. Mr. Cohen controls
    each of Point72 Asset Management, Point72 Capital Advisors Inc., and Cubist Systematic
    Strategies.  The filing of this statement should not be construed as an admission that any of the
    foregoing persons or any reporting person is, for the purposes of Section 13 of the Act, the
    beneficial owner of the Ordinary Shares reported herein.

    Item 5. Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof
    the reporting person has ceased to be the beneficial owner of more than
    5 percent of the class of securities, check the following [X].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    See Item 2(a)

    Item 7.  Identification and Classification of the Subsidiary Which Acquired
    the Security Being Reporting on by the Parent Holding Company or Control
    Person.

    Not applicable

    Item 8. Identification and Classification of Members of the Group

    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief,
    the securities referred to above were not acquired and are not held for the purpose
    of or with the effect of changing or influencing the control of the issuer of
    the securities and were not acquired and are not held in connection with or
    as a participant in any transaction having that purpose or effect.

    Signature.  After reasonable inquiry and to the best of my knowledge and belief,
    I certify that the information set forth in this statement is true, complete
    and correct.


    Dated: February 14, 2023


    POINT72 ASSET MANAGEMENT, L.P.

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    POINT72 CAPITAL ADVISORS, INC.

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    CUBIST SYSTEMATIC STRATEGIES, LLC

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    STEVEN A. COHEN

    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    Get the next $ACHL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACHL

    DatePrice TargetRatingAnalyst
    4/5/2024$8.00 → $2.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $ACHL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Achilles Therapeutics Announces Voluntary Nasdaq Delisting and SEC Deregistration

    LONDON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) (the Company) today announced that it has formally notified The Nasdaq Stock Market LLC (Nasdaq) of its intention to voluntarily delist its American Depositary Shares (ADSs) from Nasdaq and its intent to deregister its ADSs from the Securities and Exchange Commission (SEC) under Section 12(b) of the Securities Exchange Act of 1934 (Exchange Act). As previously reported, the Company has called a General Meeting for March 20, 2025 to obtain shareholder approval to commence a members' voluntary liquidation. The planned delisting of the ADSs is being undertaken in connection with the contemplated liquidation. Th

    2/28/25 7:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca

    - Proprietary data and samples from TRACERx and Achilles' Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction - - Conclusion of Strategic Review - LONDON, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) today announced that it has transferred the commercial license of data and samples from the TRACERx® Non-Small Cell Lung Cancer (NSCLC) study to AstraZeneca (NASDAQ:AZN). TRACERx (TRAcking Cancer Evolution through therapy (Rx)), led by Professor Charles Swanton at University College London (UCL), UK, is one of the largest tumor evolution studies to generate deep sequencing multi-region and multi-time-point genetic data

    12/24/24 9:30:00 AM ET
    $ACHL
    $AZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market

    LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) today announced that on November 15, 2024, the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") approved the Company's request to transfer the listing of the Company's American Depositary Shares (the "ADSs") from the Nasdaq Global Market to the Nasdaq Capital Market. The transfer is expected to take effect at the opening of business on November 19, 2024. The transfer of the Company's listing to the Nasdaq Capital Market is not expected to have any impact on trading in the Company's ADSs. The Company's ADSs will continue to trade under the symbol "ACHL." The approval by Nasdaq w

    11/19/24 7:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Achilles Therapeutics downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Achilles Therapeutics from Overweight to Neutral and set a new price target of $2.00 from $8.00 previously

    4/5/24 7:22:16 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    SEC Filings

    View All

    SEC Form 15-12G filed by Achilles Therapeutics plc

    15-12G - Achilles Therapeutics plc (0001830749) (Filer)

    3/21/25 9:41:03 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Achilles Therapeutics plc

    6-K - Achilles Therapeutics plc (0001830749) (Filer)

    3/20/25 5:30:00 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 POS filed by Achilles Therapeutics plc

    S-8 POS - Achilles Therapeutics plc (0001830749) (Filer)

    3/19/25 4:16:04 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    Leadership Updates

    Live Leadership Updates

    View All

    Achilles Therapeutics Appoints James Taylor as Chief Business Officer and Cassian Yee, MD to Scientific Advisory Board

    LONDON, June 30, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of James Taylor as Chief Business Officer and Cassian Yee, MD to its Scientific Advisory Board (SAB), effective July 1, 2022. James brings over 25 years of value-creating deal experience that includes global platform and asset deals for pharmaceutical and biotechnology companies. Most recently, he was Chief Business Officer at Sosei Heptares, where he completed a major collaboration with Neurocrine Biosciences for a Phase II-ready M4 agonist for schizophrenia, and led deals

    6/30/22 8:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Achilles Therapeutics Appoints Bernhard Ehmer to Board of Directors

    LONDON, May 04, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of Bernhard Ehmer, MD, to the Board as a Non-Executive Director. Bernhard joins Achilles with a strong track record in international R&D, regulatory and commercial activities. Bernhard is a veteran biotechnology and pharmaceutical executive with more than three decades in senior leadership roles. He most recently served as CEO of Biotest AG in Germany and also served as chairman of the board of directors at Symphogen A/S, Denmark until its acquisition by Servier SA in June 2

    5/4/22 8:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Achilles Therapeutics Strengthens Scientific Advisory Board with Appointment of Alena Gros, Ph.D. and Ben Creelan, M.D.

    LONDON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the appointment of Alena Gros, Ph.D. and Ben Creelan, M.D. to its Scientific Advisory Board (SAB). "We are very pleased to welcome leading experts Dr. Gros and Dr. Creelan to our Scientific Advisory Board. With two ongoing clinical trials, CHIRON in non-small cell lung cancer (NSCLC) and THETIS in melanoma, their extensive research experience and deep clinical expertise with cell-based immunotherapies for the treatment of solid tumors will be invaluable as we continue to advance the clinic

    2/7/22 7:30:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Achilles Therapeutics plc

    SC 13G/A - Achilles Therapeutics plc (0001830749) (Subject)

    11/14/24 4:23:04 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Achilles Therapeutics plc

    SC 13G - Achilles Therapeutics plc (0001830749) (Subject)

    9/25/24 7:14:31 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Achilles Therapeutics plc (Amendment)

    SC 13G/A - Achilles Therapeutics plc (0001830749) (Subject)

    3/29/24 4:30:59 PM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACHL
    Financials

    Live finance-specific insights

    View All

    Achilles Therapeutics Reports Third Quarter 2024 Financial Results

    – Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 –         LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL) today announced its financial results for the third quarter ended September 30, 2024, and recent corporate updates. Corporate Updates Following the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical trials, the Company has engaged BofA Securities as a financial advisor in the process of exploring strategic options.Achilles Chief Scientific Officer, Sergio Quezada, presented "Targeting Clonal Neoantigens with Pre

    11/14/24 7:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates

    – Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles' AI-powered, tumor-targeting technology – – Provided interim Phase I/IIa update on the use of cNeT in Advanced NSCLC and Melanoma including first patients with enhanced host conditioning (EHC), with the first three EHC patients showing improved cNeT persistence and engraftment – – Cash position of $95.1 million supports operations through 2025 – LONDON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid t

    8/14/24 7:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

    – Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Evaluating the benefit of enhanced host conditioning with further data expected in 2H 2024 – – Strong cash position of $112.3 million supports operations through 2025 – LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ:ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and recent business highlights. "Just after the close of the first quarter, we shared the interim Phase I/

    5/8/24 7:00:00 AM ET
    $ACHL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care